AZD-1390

Last updated
AZD-1390
AZD-1390.svg
Legal status
Legal status
  • Investigational
Identifiers
  • 7-Fluoro-3-methyl-8-[6-(3-piperidin-1-ylpropoxy)pyridin-3-yl]-1-propan-2-ylimidazo[4,5-c]quinolin-2-one
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C27H32FN5O2
Molar mass 477.584 g·mol−1
3D model (JSmol)
  • CC(C)N1C2=C(C=NC3=CC(=C(C=C32)C4=CN=C(C=C4)OCCCN5CCCCC5)F)N(C1=O)C
  • InChI=1S/C27H32FN5O2/c1-18(2)33-26-21-14-20(22(28)15-23(21)29-17-24(26)31(3)27(33)34)19-8-9-25(30-16-19)35-13-7-12-32-10-5-4-6-11-32/h8-9,14-18H,4-7,10-13H2,1-3H3
  • Key:VQSZIPCGAGVRRP-UHFFFAOYSA-N

AZD-1390 is an experimental anticancer drug developed by AstraZeneca that inhibits ataxia telangiectasia mutated (ATM). [1] [2] [3] [4] [5] [6] [7]

References

  1. ↑ Dexheimer, Thomas S.; Coussens, Nathan P.; Silvers, Thomas; Wright, John; Morris, Joel; Doroshow, James H.; Teicher, Beverly A. (25 August 2023). "Multicellular Complex Tumor Spheroid Response to DNA Repair Inhibitors in Combination with DNA-damaging Drugs". Cancer Research Communications. 3 (8): 1648–1661. doi:10.1158/2767-9764.CRC-23-0193. PMC   10452929 . PMID   37637936.
  2. ↑ Bannik, Kristina; Madas, Balázs; Jarke, Sabrina; Sutter, Andreas; Siemeister, Gerhard; Schatz, Christoph; Mumberg, Dominik; Zitzmann-Kolbe, Sabine (1 December 2021). "DNA repair inhibitors sensitize cells differently to high and low LET radiation". Scientific Reports. 11 (1): 23257. Bibcode:2021NatSR..1123257B. doi:10.1038/s41598-021-02719-9. PMC   8636489 . PMID   34853427.
  3. ↑ Guha, Lahanya; Kumar, Hemant (November 2023). "Drug Repurposing for Spinal Cord Injury: Progress Towards Therapeutic Intervention for Primary Factors and Secondary Complications". Pharmaceutical Medicine. 37 (6): 463–490. doi:10.1007/s40290-023-00499-3. PMID   37698762. S2CID   261694463.
  4. ↑ Fischer, Thomas; Hartmann, Oliver; Reissland, Michaela; Prieto-Garcia, Cristian; Klann, Kevin; Pahor, Nikolett; Schülein-Völk, Christina; Baluapuri, Apoorva; Polat, Bülent; Abazari, Arya; Gerhard-Hartmann, Elena; Kopp, Hans-Georg; Essmann, Frank; Rosenfeldt, Mathias; Münch, Christian; Flentje, Michael; Diefenbacher, Markus E. (27 April 2022). "PTEN mutant non-small cell lung cancer require ATM to suppress pro-apoptotic signalling and evade radiotherapy". Cell & Bioscience. 12 (1): 50. doi: 10.1186/s13578-022-00778-7 . PMC   9044846 . PMID   35477555.
  5. ↑ Qi, Yinliang; Wang, Kun; Long, Bin; Yue, Hao; Wu, Yongshuo; Yang, Dexiao; Tong, Minghui; Shi, Xuan; Hou, Yunlei; Zhao, Yanfang (January 2023). "Discovery of novel 7,7-dimethyl-6,7-dihydro-5H-pyrrolo[3,4-d]pyrimidines as ATR inhibitors based on structure-based drug design". European Journal of Medicinal Chemistry. 246: 114945. doi:10.1016/j.ejmech.2022.114945. PMID   36462444. S2CID   254175697.
  6. ↑ Teicher, Beverly A.; Doyle, Austin; Wright, John; Kunos, Charles; Silvers, Thomas; Delosh, Rene; Laudeman, Julie; Reinhart, Russell; Ogle, Chad; Coussens, Nathan; Morris, Joel; Doroshow, James (15 August 2020). "Abstract 328: DNA damage inhibitors with topotecan in a complex spheroid model in PDM and established cell lines". Cancer Research. 80 (16_Supplement): 328. doi:10.1158/1538-7445.AM2020-328. S2CID   225347744.
  7. ↑ Coussens, Nathan P.; Parchment, Ralph E.; Moscow, Jeffrey A.; Doyle, L. Austin; Delosh, René; Laudeman, Julie; Reinhart, Russell; Ogle, Chad; Silvers, Thomas; Dexheimer, Thomas S.; Morris, Joel; Teicher, Beverly A.; Doroshow, James H. (1 July 2021). "Abstract 1072: Combination screening of DNA damaging agents temozolomide and trabectedin with inhibitors of DNA repair using a complex spheroid model with a panel of patient-derived and established tumor cell lines". Cancer Research. 81 (13_Supplement): 1072. doi:10.1158/1538-7445.AM2021-1072. S2CID   237868861.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.